Clinical Trial

Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated July 29, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy in the Bangladeshi population. Researchers will compare atorvastatin (10 mg) and ezetimibe (10 mg) to atorvastatin (20 mg) monotherapy to see if atorvastatin (10 mg) and ezetimibe (10 mg) FDC works to treat dyslipidemia. Participants will: * Take a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy for 3 months * Follow-up visits at 6 weeks and 12 weeks for checkups and tests
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-22; most recent amendment 2025-07-25.
Status change: Not Yet Recruiting → Recruiting 2025-07-25
Trial Details
NCT Number NCT06789432
Lead Sponsor Dr. Md. Alimur Reza
Conditions Hyperlipidemia (E.G., Hypercholesterolemia)
Enrollment 500 participants
Start Date 2025-02-01
Primary Completion 2025-10 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-29